First Horizon Advisors, Inc. Biogen Inc. Transaction History

First Horizon Advisors, Inc.

$3.58 Billion
Q3 2024

A detailed history of First Horizon Advisors, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 182 shares of BIIB stock, worth $28,737. This represents 0.0% of its overall portfolio holdings.

Number of Shares

182

Previous 172 5.81%

Holding current value

$28,737

Previous $39,000 10.26%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$189.07 - $236.8 $1,890 - $2,368	10 Added 5.81%	182 $35,000
Q2 2024 Jul 19, 2024	BUY	$190.52 - $236.72 $9,335 - $11,599	49 Added 39.84%	172 $39,000
Q1 2024 Apr 26, 2024	SELL	$212.02 - $267.71 $18,657 - $23,558	-88 Reduced 41.71%	123 $26,000
Q4 2023 Feb 06, 2024	SELL	$222.59 - $267.94 $14,913 - $17,951	-67 Reduced 24.1%	211 $54,000
Q3 2023 Oct 27, 2023	SELL	$253.3 - $285.89 $116,518 - $131,509	-460 Reduced 62.33%	278 $71,000
Q2 2023 Aug 03, 2023	SELL	$275.25 - $318.06 $22,845 - $26,398	-83 Reduced 10.11%	738 $210,000
Q1 2023 May 15, 2023	SELL	$256.56 - $292.34 $34,379 - $39,173	-134 Reduced 14.03%	821 $228,000
Q4 2022 Feb 10, 2023	SELL	$252.44 - $306.72 $134,045 - $162,868	-531 Reduced 35.73%	955 $264,000
Q3 2022 Nov 09, 2022	BUY	$194.69 - $268.46 $3,893 - $5,369	20 Added 1.36%	1,486 $396,000
Q2 2022 Aug 02, 2022	SELL	$187.54 - $223.02 $736,844 - $876,245	-3,929 Reduced 72.83%	1,466 $298,000
Q1 2022 May 10, 2022	SELL	$193.77 - $244.14 $2.33 Million - $2.93 Million	-12,007 Reduced 69.0%	5,395 $1.14 Million
Q4 2021 Feb 09, 2022	SELL	$223.92 - $287.77 $212,724 - $273,381	-950 Reduced 5.18%	17,402 $4.18 Million
Q3 2021 Nov 15, 2021	SELL	$282.99 - $369.05 $4.11 Million - $5.35 Million	-14,506 Reduced 44.15%	18,352 $5.19 Million
Q3 2021 Nov 09, 2021	BUY	$282.99 - $369.05 $4.35 Million - $5.67 Million	15,372 Added 87.91%	32,858 $9.3 Million
Q2 2021 Aug 09, 2021	SELL	$259.0 - $414.71 $48,433 - $77,550	-187 Reduced 1.06%	17,486 $6.05 Million
Q1 2021 May 11, 2021	BUY	$242.95 - $284.63 $113,214 - $132,637	466 Added 2.71%	17,673 $4.94 Million
Q4 2020 Feb 11, 2021	SELL	$236.26 - $355.63 $77,493 - $116,646	-328 Reduced 1.87%	17,207 $4.21 Million
Q3 2020 Nov 12, 2020	SELL	$264.77 - $305.71 $13,768 - $15,896	-52 Reduced 0.3%	17,535 $4.97 Million
Q2 2020 Jul 31, 2020	BUY	$258.66 - $342.55 $37,764 - $50,012	146 Added 0.84%	17,587 $4.71 Million
Q1 2020 May 05, 2020	SELL	$268.85 - $341.04 $123,133 - $156,196	-458 Reduced 2.56%	17,441 $5.52 Million
Q4 2019 Jan 07, 2020	SELL	$220.06 - $304.07 $112,890 - $155,987	-513 Reduced 2.79%	17,899 $5.31 Million
Q3 2019 Oct 23, 2019	BUY	$217.44 - $243.88 $673,411 - $755,296	3,097 Added 20.22%	18,412 $4.29 Million
Q2 2019 Aug 05, 2019	BUY	$219.29 - $241.72 $98,461 - $108,532	449 Added 3.02%	15,315 $0
Q1 2019 Apr 26, 2019	BUY	$216.71 - $338.96 $207,174 - $324,045	956 Added 6.87%	14,866 $0
Q4 2018 Feb 11, 2019	SELL	$278.5 - $352.75 $446,992 - $566,163	-1,605 Reduced 10.34%	13,910 $4.19 Million
Q3 2018 Nov 05, 2018	BUY	$293.51 - $383.83 $3.72 Million - $4.87 Million	12,682 Added 447.65%	15,515 $0
Q3 2018 Nov 05, 2018	SELL	$293.51 - $383.83 $3.84 Million - $5.02 Million	-13,083 Reduced 82.2%	2,833 $0
Q2 2018 Aug 07, 2018	BUY	$257.52 - $306.91 $16,481 - $19,642	64 Added 0.4%	15,916 $0
Q1 2018 May 02, 2018	SELL	$260.13 - $367.91 $184,692 - $261,216	-710 Reduced 4.29%	15,852 $0
Q4 2017 Jan 25, 2018	SELL	$307.64 - $344.58 $79,678 - $89,246	-259 Reduced 1.54%	16,562 $0
Q3 2017 Nov 09, 2017	SELL	$281.15 - $329.69 $29,801 - $34,947	-106 Reduced 0.63%	16,821 $0
Q2 2017 Aug 14, 2017	BUY	N/A	16,927	16,927 $0

Others Institutions Holding BIIB

# of Institutions

1,036

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $22.7B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Horizon Advisors, Inc. with notifications on news.

Account

First Horizon Advisors, Inc. Biogen Inc. Transaction History